In this Pharmaceutical Executive article, Dr. Andrew Rut discusses the importance of capturing robust data to assess the safety and efficacy of new treatments and vaccines for COVID-19. Dr Rut shares his views on the role of Large Simple Trials in understanding benefit-risk across broad populations given the potential impact of confounding factors such as preexisting conditions on drug safety and efficacy. Finally he discusses how digital technology can streamline drug safety reporting processes and transfer robust, accurate data direct to pharmacovigilance teams.
Read the full article 'What is Required of Drug Safety During the COVID-19 Pandemic?'.
